Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generative AI-Based Drug Design: Target-Aware Molecular Generation for EGFR Type I Inhibitors with Multiplatform Docking Validation.

ACS omega·2026
Same author

ASO Author Reflections: Calibrating Lymph Node Metastasis Risk After Non-curative Endoscopic Resection of pT1 Colorectal Cancer.

Annals of surgical oncology·2026
Same author

Cold-spot driven local failure after stereotactic body radiation therapy for colorectal liver metastases.

Frontiers in oncology·2026
Same author

APB-FLDPA: Adaptive Personalized Blockchain-Federated Learning With Differential Privacy and Attention for Privacy-Preserving Healthcare Analytics.

Healthcare technology letters·2026
Same author

Calibrated Absolute Risk of Lymph-Node-Metastasis After Non-curative Endoscopic Resection of pT1 Colorectal Cancer.

Annals of surgical oncology·2026
Same author

Risk factors for lymph node metastasis in p/ypT1-2 rectal cancer.

American journal of surgery·2025

Related Experiment Video

Updated: May 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.

Hae Ran Yun1, Hee Cheol Kim, Seong Hyeon Yun

  • 1Department of Surgery, Samsung Medical Center, Seoul, Korea.

Hepato-Gastroenterology
|November 22, 2012
PubMed
Summary
This summary is machine-generated.

Adjuvant chemotherapy significantly improves survival and reduces recurrence in stage IIA colon cancer patients. It is particularly beneficial for those with fewer than 15 harvested lymph nodes, alongside lymphovascular invasion as a key prognostic factor.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Related Experiment Videos

Last Updated: May 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Colon cancer staging is crucial for treatment decisions.
  • Stage IIA colon cancer requires careful consideration of adjuvant therapies.
  • Prognostic factors influence patient outcomes in early-stage colon cancer.

Purpose of the Study:

  • To identify prognostic factors in stage IIA colon cancer.
  • To evaluate the efficacy of adjuvant chemotherapy in stage IIA colon cancer.
  • To compare different adjuvant chemotherapy regimens.

Main Methods:

  • Retrospective analysis of 447 stage IIA colon cancer patients (1994-2004).
  • Comparison between surgery alone and surgery with adjuvant chemotherapy.
  • Multivariate analysis of prognostic factors including lymphovascular invasion and lymph node count.

Main Results:

  • Adjuvant chemotherapy was received by 78.5% of patients.
  • Lymphovascular invasion and adjuvant chemotherapy were significant predictors of survival.
  • Male gender, lymph node count (<15), lymphovascular invasion, and adjuvant chemotherapy predicted recurrence.
  • No significant difference in efficacy among 5-fluorouracil, capecitabine, and uracil/tegafur.

Conclusions:

  • Adjuvant chemotherapy is an independent prognostic factor for stage IIA colon cancer.
  • Adjuvant chemotherapy improves survival and reduces recurrence rates.
  • The benefit of adjuvant chemotherapy is pronounced in patients with fewer than 15 harvested lymph nodes.